display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
NSCLC neoadjuvant setting
NSCLC neoadjuvant setting
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab plus SoC CheckMate 816

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons